All In Biotech

Drug Trial Radar · NCT02065791

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

Last checked: Nov 20, 2026Latest source record: Dec 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,401 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,401

Actual

Start

Feb 17, 2014

Primary completion

Oct 30, 2018

Study completion Oct 30, 2018

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
The George Institute for Global Health, Australia
First posted
Feb 19, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD) and macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).

Conditions

  • Diabetes Mellitus, Type 2
  • Diabetic Nephropathy

Interventions

  • CanagliflozinDrug

    One 100 mg over-encapsulated tablet orally once daily

  • PlaceboDrug

    One matching placebo capsule orally (by mouth) once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End-stage Kidney Disease (ESKD), and Renal or Cardiovascular (CV) DeathTime frame: Up to 4.6 years

Locations

575 sites in 34 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Tempe, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Sherwood, Arkansas

  • Site not named

    Bakersfield, California

  • Site not named

    Chula Vista, California

  • Site not named

    Covina, California

  • Site not named

    Downey, California

  • Site not named

    Fountain Valley, California

  • Site not named

    Hawthorne, California

  • Site not named

    Inglewood, California

  • Site not named

    Laguna Hills, California

  • Site not named

    Lakewood, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Lynwood, California

  • Site not named

    Northridge, California

  • Site not named

    Oakland, California

  • Site not named

    Orange, California

  • Site not named

    Pasadena, California

  • Site not named

    Roseville, California

  • Site not named

    Sacramento, California

  • Site not named

    Salinas, California

  • Site not named

    San Diego, California

  • Site not named

    San Dimas, California

  • Site not named

    Stanford, California

  • Site not named

    Tustin, California

  • Site not named

    Whittier, California

  • Site not named

    Denver, Colorado

  • Site not named

    Golden, Colorado

  • Site not named

    Lakewood, Colorado

  • Site not named

    Washington, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Coral Springs, Florida

  • Site not named

    Doral, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

Showing 40 of 575 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.